MRA Meet Ups: Unlocking LAG-3 – New Frontiers in Combination Immunotherapy for Melanoma скачать в хорошем качестве

MRA Meet Ups: Unlocking LAG-3 – New Frontiers in Combination Immunotherapy for Melanoma

On Friday, September 26, the Melanoma Research Alliance hosted an MRA Meet Up webinar featuring Dr. Hussein Tawbi, Professor and Executive Director of the Immuno-Oncology Clinical Drug Development Program at MD Anderson Cancer Center. Dr. Tawbi explored the science behind LAG-3, the newest immune checkpoint to be validated in melanoma, and discussed how blocking LAG-3 alongside PD-1 can reinvigorate exhausted T cells and improve patient outcomes. He shared insights into Regeneron’s robust clinical development program testing the combination of fianlimab (a LAG-3-blocking drug) and cemiplimab (a PD-1-blocking drug) across four clinical trials for patients with resectable and unresectable melanoma, including head-to-head comparisons against today’s standard treatments. This session highlighted: Why LAG-3 + PD-1 combinations are promising for patients. Early results from clinical trials. Key considerations for patients thinking about enrolling in clinical trials. The important questions researchers are still working to answer, including how this combination may help patients with rare melanoma subtypes or brain metastases. This was a valuable opportunity to learn directly from one of the world’s leading melanoma experts.